Giuliano Bellapadrona

Giuliano Bellapadrona has worked in the pharmaceutical and biopharma industry since 2007. Giuliano began with a Ph.D. internship at Children's Hospital Oakland Research Institute in 2007 and then moved to the Weizmann Institute of Science as a Scientific Consultant and Postdoctoral Research Scientist from 2009 to 2015. In 2015, they joined Teva Pharmaceuticals as a Senior Scientist, Biologics CMC Biosimilars, where they developed and qualified analytical methods for 7 biosimilar projects, product characterization, and comparability assessments. In 2018, Giuliano joined NBE-Therapeutics AG as an Associate Director, Global CMC and CMC Project Coordinator, where they were involved in CMC due diligence with large pharmaceutical companies, leading to the Top20 Pharma acquisition in 2020 by Boehringer Ingelheim. Giuliano was also responsible for post-acquisition integration, tech transfer, and coordination of Late Phase CMC development, as well as the establishment of the overall analytical control strategy. Giuliano currently works at Boehringer Ingelheim as an R&D Project Leader.

Giuliano Bellapadrona began their educational career by attending Liceo Scientifico. Giuliano then went on to pursue a Master's degree in Biology, General at Sapienza Università di Roma from 1999 to 2005. Finally, they earned a Doctor of Philosophy (Ph.D.) in Biochemistry from Sapienza Università di Roma in 2009.